Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

[1] Tray N(2019)Therapeutic landscape of metaplastic breast cancer Cancer Treat Rev 79 101888-424

[2] Taff J(2019)Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease Breast J 25 418-70

[3] Adams S(2000)The hallmarks of cancer Cell 100 57-139

[4] Takala S(2019)High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients Oncoimmunology 8 e1629258-528

[5] Heikkilä P(2004)P53 Overexpression and Mutation in Metaplastic Carcinoma of the Breast: Genetic Evidence for a Monoclonal Origin of both the Carcinomatous and the Heterogeneous Sarcomatous Components J Pathol 204 131-32

[6] Nevanlinna H(2013)Molecular alterations in metaplastic breast carcinoma J Clin Pathol 66 522-870

[7] Blomqvist C(2019)Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes Breast (Edinburgh, Scotland) 44 29-1355

[8] Mattson J(2005)DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 864-2473

[9] Hanahan D(2008)An oncogene-induced DNA damage model for cancer development Science 319 1352-45

[10] Weinberg RA(2021)Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution Cancer Discov 11 2456-316

[1] Tray N(2019)Therapeutic landscape of metaplastic breast cancer Cancer Treat Rev 79 101888-424

[2] Taff J(2019)Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease Breast J 25 418-70

[3] Adams S(2000)The hallmarks of cancer Cell 100 57-139

[4] Takala S(2019)High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients Oncoimmunology 8 e1629258-528

[5] Heikkilä P(2004)P53 Overexpression and Mutation in Metaplastic Carcinoma of the Breast: Genetic Evidence for a Monoclonal Origin of both the Carcinomatous and the Heterogeneous Sarcomatous Components J Pathol 204 131-32

[6] Nevanlinna H(2013)Molecular alterations in metaplastic breast carcinoma J Clin Pathol 66 522-870

[7] Blomqvist C(2019)Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes Breast (Edinburgh, Scotland) 44 29-1355

[8] Mattson J(2005)DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 864-2473

[9] Hanahan D(2008)An oncogene-induced DNA damage model for cancer development Science 319 1352-45

[10] Weinberg RA(2021)Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution Cancer Discov 11 2456-316